Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.

ABSTRACT:

Aims

Immune-related adverse events(irAEs) are common among cancer patients receiving dual immune checkpoint inhibitors (ICI). Cardiac adverse events rank among the most severe categories of such reactions. This study aims to investigate the characteristics and influencing factors of cardiac adverse events associated with dual ICIs.

Methods and results

We collected data on cardiac adverse events associated to dual ICIs from the US Food and Drug Administration Adverse Event Reporting System database (FAERS), covering the period from the first quarter of 2015 to the fourth quarter of 2024. A disproportionality analysis was performed to assess the association between different dual ICIs and cardiac adverse events, and a comprehensive study was conducted to identify potential inf

SUBMITTER: Xia H 

PROVIDER: S-EPMC12946970 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature